Decades before the onset of mild cognitive impairment (MCI), amyloid beta (Aβ) begins accumulating in the brain, contributing to neurodegeneration. In the amyloid cascade model of AD, the continuous accumulation of Aβ underlies the irreversible, ongoing nature of neurodegeneration within AD1.
Learning Zone
Review self-guided learning decks on topics, including the underlying pathophysiology of the disease and etiological hypotheses, risk factors for AD, the AD continuum, the evolving patient journey, and much more.
Practical Zone
Review self-guided learning decks with a more practical focus of diagnosing Alzheimer’s disease that will include case studies to frame key diagnostic steps — more case studies coming soon!
Visual and Video Zone
Review visual flashcards for quick learning topics on AD or hear experts present case studies of a patient’s journey through an early diagnosis, some of the challenges that can impact early diagnosis and operational insights on how to try to overcome them.
Video Lectures
Challenges and solutions for a timely
diagnosis of AD
Viewing time: 8 minutes 40 seconds
Speaker: Dr. Malaz Boustani
Watch this presentation to understand the benefits of an early diagnosis and the challenges primary care providers face in achieving this. As part of this presentation, Dr. Boustani summarizes unmet needs in the current clinical care pathway for AD and possible solutions on the horizon to address these.
Patient and caregiver barriers to a timely
diagnosis of AD
Viewing time: 8 minutes 30 seconds
Speaker: Dr. Malaz Boustani
In this presentation, Dr. Boustani discusses the factors that influence an individual’s acceptance of dementia screening and the negative impact of societal stigma on early diagnosis of AD and defines the key changes needed to address these challenges and prepare healthcare systems for the timely detection of AD.
When should neuroimaging be performed during a diagnostic workup for AD?
Viewing time: 3 minutes
Speaker: Dr. Ana Franceschi
Watch this video to understand when, in the diagnostic pathway, neuroimaging can support a diagnosis of AD. Dr. Franceschi will briefly summarize the imaging modalities available that can help separate patients with underlying AD pathology from other neurodegenerative disorders.
Expert Insights
The Early Alzheimer’s Disease Patient Care Pathway (including anti-amyloid monoclonal antibody treatment) – A Health System Readiness and Implementation Guide
Viewing time: 45 minutes
Speakers:
•David S. Geldmacher, MD, FANA, FACP, Director, Division of Cognitive and Behavioral Neurology University of Alabama at Birmingham
•Pierre Tariot, MD Director, Banner Alzheimer’s Institute, Research Professor of Psychiatry University of Arizona College of Medicine
•Moderator: Jeff Vawter, MHA, Sr. Director, Research Sciences - Premier Inc.
Watch this webinar with Dr. David Geldmacher and Dr. Pierre Tariot to learn how healthcare providers may adapt the Early AD Patient Care Pathway to various healthcare settings to ensure timely intervention, effective treatment and continuous support throughout the disease trajectory.
Access the Early AD Patient Care Pathway
Clinical practice considerations for fluid
biomarkers in AD
Viewing time: 21 minutes
Speaker: Dr Suzanne Schindler
In this interview, Dr Suzanne Schindler addresses questions on how fluid biomarkers of AD are being used in the clinic. She discusses the clinical use of biomarkers in the context of a typical diagnostic pathway and navigates important topics including their diagnostic accuracy, ethical considerations, and healthcare infrastructural requirements to support their implementation.
Infographics
References
- Hampel H, et al. Mol Psychiatry. 2021;26(10):5481–5503.